James Lind Alliance research priorities:Should diet and exercise be used as an alternative to drugs for the management of Type 2 diabetes or alongside them? by England, Clare Y & Andrews, Robert C
                          England, C. Y., & Andrews, R. C. (2019). James Lind Alliance
research priorities: Should diet and exercise be used as an alternative
to drugs for the management of Type 2 diabetes or alongside them? .
Diabetic Medicine. https://doi.org/10.1111/dme.14217
Peer reviewed version
Link to published version (if available):
10.1111/dme.14217
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Wiley at https://doi.org/10.1111/dme.14217 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the




Lifestyle vs drugs 
Title: James Lind Alliance research priorities: Should diet and exercise be used as an 
alternative to drugs for the management of Type 2 diabetes or alongside them? 
Running title: Lifestyle vs drugs 
Authors: 
Clare Y. England1,2 and Robert C. Andrews3, 4 
1National Institute for Health Research Bristol Biomedical Research Centre, University 
Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK 
2Centre for Exercise Nutrition and Health Sciences, School for Policy Studies, University of 
Bristol, Bristol, UK 
3Department of Diabetes, Taunton and Somerset NHS Foundation Trust, Taunton, UK 
4University of Exeter Medical School, Exeter, UK 
Corresponding author: Clare England: clare.england@bristol.ac.uk 
 
Manuscript word count: 4291 
Abstract word count: 247 
 
Conflict of interest: None declared 
Acknowledgements: CE is funded by the NIHR Biomedical Research Centre at University 
Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed are 
those of the authors and not necessarily those of the NIHR or the Department of Health and 
Social Care. 
Novelty statement 
• Interactions between physical activity and glucose lowering medications have been 
observed but are not well understood and there is little research into the interactions 
between medication and overall diet patterns. 
• Few interventions compare lifestyle with drug therapy or control for medication use. 
At present available evidence indicates that most people will eventually need drug 
therapy in addition to lifestyle. 
• There is little evidence for how best to support people in maintaining weight loss or 
physical activity for the long-term. Improving maintenance strategies may help more 
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James Lindt Alliance research priorities: Should diet and exercise be used as an alternative 
to drugs for the management of type 2 diabetes or alongside them? 
Abstract 
Aims 
The aim is to review evidence on whether diet and exercise should be used as an alternative 
to drug therapy for the management of type 2 diabetes or alongside.  
Method 
We present a narrative review that draws on evidence from other systematic reviews and 
meta-analyses, narrative reviews, trials and cohort studies. We focussed mainly on glycaemic 
control rather than control of blood pressure or cholesterol. 
Results 
Good quality dietary advice that results in weight loss of >5% and physical activity 
interventions of >150mins/week moderate to vigorous physical activity combined with 
resistance exercise can produce improvements to HbA1c similar to that produced by the 
addition of glucose lowering drugs. These improvements can be seen at all stages of the 
disease. There are recognised interactions between glucose lowering drugs and physical 
activity which may not be synergistic, but these are not well understood, and it is not clear if 
they are considered in clinical practice. Studies that explicitly compare drugs with diet or 
physical activity or control for drug use found lifestyle could delay or reduce medication, but 
most people eventually needed to progress onto drug treatment. However, there are few 
studies that provide strategies for long-term maintenance of weight loss or physical activity. 
Conclusion 
Diet and physical activity are of key importance in type 2 diabetes management and attention 
to them improves glycaemic control and cardiovascular disease risk, but it is not yet known 
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Introduction 
In the UK, the National Institute for Health and Care Excellence advises that, if HbA1c rises to 
48mmol/mol (6.5%), adults with type 2 diabetes should start medication, with metformin as 
the first-line drug if tolerated [1]. Similarly, the American Diabetes Association and the 
European Association for the Study of Diabetes advise that drug therapy should be started on 
diagnosis [2]. The guidelines also indicate that lifestyle management, which includes dietary 
advice/medical nutrition therapy and physical activity is necessary, but diet and physical 
activity are presented as an adjunct to drug therapy rather than an alternative.  
However, in 2015 the Diabetes UK-James Lind Alliance Priority Setting Partnership in Type 2 
diabetes published a list of ten research priorities to highlight unanswered questions and 
areas of uncertainty [3]. One of the priorities was to ask if diet and exercise should be used as 
an alternative to drugs in the management of type 2 diabetes or alongside them. This question 
recognises that people do not find drug therapy straightforward, and that medications can 
produce side-effects [4]. In contrast diet and physical activity have few side effects [2] and 
there is evidence that they can reduce or delay the need for medication [5-8]. People with 
type 2 diabetes and health professionals would like more research on how to decide which 
approach to treatment is best for each person, recognising that not all people with type 2 
diabetes may benefit from drugs or diet or physical activity in the same manner.  
This review provides an overview of the literature on diet and physical activity alongside or 
instead of drug therapy, with a focus on the management of hyperglycaemia with type 2 
diabetes prior to insulin initiation. We have taken a broad approach to the topic and have not 
attempted a systematic review. Instead, we have drawn evidence from systematic and other 
narrative reviews and relevant randomised controlled trials and cohort studies to ask: 1) What 
can diet, and physical activity achieve? 2) What is known about interactions between diet or 
physical activity and drugs? 3) What can diet, and physical activity achieve in comparison with 
drugs? 4) Should there be an individualised approach for stage, age, gender and ethnicity? 
This review does not include detailed examinations of remission of type 2 diabetes through 
diet or whether there is an ideal macronutrient ratio for type 2 diabetes since these questions 
have been addressed by other reviews in this series [9, 10]. 
1) What can diet, and physical activity achieve? 
Effect of diet advice on HbA1c 
Dietary advice or Medical Nutrition Therapy is the cornerstone of treatment for type 2 
diabetes and is an important part of Diabetes Self-Management Education and Support [2, 
11]. Figure 1 outlines the benefits that can be achieved with diet and physical activity in 
people with type 2 diabetes. 
There is little evidence for the superiority of one dietary approach over another or for an ideal 
macronutrient ratio so an individualised approach is recommended [10-12]. There is evidence 
that high quality dietary advice can improve HbA1c from a systematic review showing that 
dietary advice given by dietitians can reduce HbA1c by 3mmol/mol to 22mmol/mol (0.3% - 
2.0%). For comparison, oral medications are expected to improve HbA1c by around 
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11mmol/mol (1.0%) [2]. A recent systematic review of behavioural determinants of good 
glycaemic control found that dietary adherence was the most important determinate [13], 
reported that the behavioural factor that best predicted HbA1c was dietary adherence (the 
other behavioural factors included were adherence to physical activity, medications, glucose 
self-monitoring and appointment keeping.  
There is some evidence that specific diets (Mediterranean diet, a low fat vegan diet and a low 
glycaemic index diet) may improve glycaemic control independently of weight loss [14]. 
However,  there is more evidence that dietary advice for T2D should prioritise weight loss for 
those who are overweight, and avoidance of weight gain for those of normal weight [11, 12]. 
A 2015 meta-analysis of 11 lifestyle weight-loss studies [15] found eight that reported a 
weight loss of <5% at 12months which was associated with an improvement of HbA1c of 
2mmol/mol (95% CI, -7 to 2mmol/mol) (0.2% (95% CI: −0.6 to 0.2%)). This is in comparison to 
two studies where participants achieved a weight loss of ≥5% in the intervention arms. An 
improvement in HbA1c of 13mmol/mol (95% CI, -15 to 12 mmol/mol) (1.2% (95% CI, -1.4 to -
1.1%)) was seen in a Mediterranean diet study, conducted by Esposito et al [16]. The Look 
Ahead study, the largest randomised controlled lifestyle-based intervention conducted in 
people with T2D to date, reported an improvement in HbA1c of 7mmol/mol (95% CI, -8 to -
7mmol/mol) (0.6% (95% CI, -0.7 to -0.6%)) [17]. Further analysis of Look AHEAD indicated that 
improvements in HbA1c were greater with greater weight reduction. The Diabetes Remission 
Clinical Trial (DiRECT) demonstrated that weight loss of 15kg through diet alone can bring 
about remission of T2D [9].  
Other benefits of dietary advice 
As well as improving HbA1c, diet can result in other improvements if weight-loss is over 5%. 
In the Look Ahead study, participants in the intensive lifestyle intervention saw improved lipid 
control, less sleep apnoea, lower liver fat, improved insulin resistance, less kidney disease and 
improved quality of life[8]. In the longer term, analysis of data from the Anglo-Danish-Dutch 
Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care 
(ADDITION)-Cambridge found that weight loss of ≥5% in the first year of diagnosis was 
associated with a 48% lower risk of cardiovascular disease at 10 years (HR 0.52 (95% CI 0.32, 
0.86)) [18]. 
Effect of physical activity on HBA1c 
Physical activity, both alone and in combination with dietary advice, has also been observed 
to lower HbA1c. A 2011 meta-analyses of structured physical activity interventions[19] 
reported reductions in HbA1c of 7mmol/mol (95% CI, -9 to -5mmol/mol) (-0.7%; 95% CI, to -
0.4 to -0.5%), with greater improvements associated with more than 150mins/week 
structured activity. Physical activity advice alone was not found to improve HbA1c but when 
given in combination with dietary advice, HbA1c improved by 6mmol/mol (95% CI, -8 to -
5mmol/mol) (-0.6%; 95% CI, -0.7 to -0.4%).  
Two randomised controlled trials have attempted to clarify what form of supervised exercise 
is best. In the Diabetes Aerobic and Resistance Exercise trial [20], combined aerobic and 
resistance produced an additional 5mmol/mol (95% CI, 9 to 1mmol/mol) (0.5% (95% CI, -0.8 
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to -0.1%) fall in HbA1c compared with the aerobic group and 6mmol/mol (95% CI, -10 to -
3mmol/mol) (-0.6 % (95% CI, -0.95 to -0.23%) compared with the resistance group. In people 
with HbA1c ≤ 58mmol/mol (7.5%), HbA1c only decreased significantly in the combined 
exercise training group.  Church et al [21] also found that when compared with a control 
group, neither resistance nor aerobic training alone produced a significant change in HbA1c.  
However, for the combination training exercise group, a fall in HbA1c of 3mmol/mol (0.3%) 
was seen compared to the control group. Based on this evidence, the American Diabetes 
Association recommend people with type 2 diabetes undertake at least 150 min per week of 
moderate to vigorous aerobic exercise with two to three sessions per week of resistance 
exercise on non‐consecutive days [11]. 
High-intensity interval training (HIT) is the newest form of exercise to be tried in the 
management of type 2 diabetes as it takes less time to perform and can produce similar 
metabolic effects to longer duration of standard exercises. A meta-analysis of four small 
studies showed that compared with control conditions, in people with type 2 diabetes, HIT 
decreased HbA1c by 2mmol/mol (0.2%) [22]. HIT was not superior to continuous training at 
lowering HbA1c, however it did improve fitness to a greater extent. [23]. 
Other benefits of physical activity 
Like diet, regular physical activity can provide additional benefits over and above its effects 
on HbA1c.  Regular physical activity improves blood pressure, lipid control, fitness and 
vascular function with greater improvements seen with more than 150 minutes/week  of 
activity [24]. A systematic review of reported that evidence from epidemiological and 
observational studies in patient with type 2 diabetes found strong associations between 
higher levels of physical activity and reduction in mortality [25]. However, intervention 
studies found that physical activity improved cardiovascular risk factors, but the increase in 
activity and the observed improvements did not always persist after active counselling 
ceased. 
 
2) Interactions between diet, physical activity and drugs.  
Interaction between diet and dipeptidyl peptidase-4 (DPP-4) inhibitors 
We could find few studies that had a specific aim of examining the interactions between 
dietary intake and drugs in type 2 diabetes. It has been suggested in a systematic review that 
acarbose is more effective in people consuming an Eastern diet than a Western diet due to 
higher starch intake, but it is not clear whether the included studies measured diet [26]. 
Similarly, no studies have looked at whether the addition of drug therapies impacts on 
adherence to dietary advice.  The type of meal, order in which food is eaten during a meal, 
timing of meals and speed in which people eat have all been shown to have an effect on GLP-
1 plasma concentrations [27]. For this reason, some small studies have tried to determine 
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An increased in dietary fat, especially saturated fat, has been associated with greater 
deterioration in the HbA1c lowering effect of DPP-4 inhibitors over time [28].  Higher serum 
levels of a dietary marker that correlates with fish intake (serum eicosapentaenoic acid) has 
been associated with a greater fall in HbA1c when starting a DPP-4 inhibitor [29]. 
Interaction of physical activity and drugs 
More evidence is available for interactions between physical activity and drugs but again this 
has tended to concentrate on supervised exercise and has not looked at whether the addition 
of drug therapy impacts on adherence to exercise advice. Eckstein et al have recently 
reviewed the interactions between exercise and non-insulin glucose lowering therapies [30]. 
Table 1 summarises what is known.  
Physical activity and drugs that improve insulin resistance 
Metformin and thiazolidinediones both work by helping to increase insulin sensitivity. Three 
randomised controlled trials which looked at the acute effect of metformin in combination 
with exercise found that although metformin may reduce the fall in glucose during exercise, 
glucose control over 24 hours was similar to those who exercised without metformin [31-33]. 
Sub-analysis of data from The Look Ahead Study. found that addition of metformin, in the 
long-term to intense lifestyle was found to result in no additional improvement in HbA1c [34]. 
In a study of people newly diagnosed with of type 2 diabetes, pioglitazone enhanced exercise-
stimulated skeletal muscle uptake [33]. In a sub-analysis of the Insulin Resistance After stroke 
study the HbA1c fall over 20 weeks with pioglitazone was independent of self-reported levels 
of physical activity [35]. 
Physical activity and drugs that improve insulin secretion 
Both sulfonylureas and glinides act by increasing insulin release from pancreatic beta cells. In 
a number of studies, exercising with sulfonylureas results in a greater fall in glucose driven by 
higher insulin levels [36-38]. This increases the risk of hypoglycaemia during exercise, 
particularly if the exercise is continuous low intensity exercise and the starting glucose 
concentration is low. No studies have looked at the long-term interaction of sulfonylureas and 
exercise. Little is known about either the acute or chronic interaction of glinides and exercise.  
Physical activity and drugs that improve insulin GLP plasma concentrations 
GLP-1RA and DPP-4 inhibitors act by increasing GLP-1 plasma concentrations, which in turn 
stimulate insulin release and inhibit glucagon release from the pancreas. In participants with 
type 2 diabetes, liraglutide (a GLP1-RA) added to a 16 week exercise programme resulted in 
a greater fall in HbA1c, weight and blood pressure compared to exercise alone [39]. 
Physical activity and SGLT-2 inhibitors 
The sodium-glucose co-transporter-2 (SGLT-2) inhibitors prevent the re-uptake of glucose in 
the proximal convoluted tubule of the kidney resulting an increase in urinary glucose 
excretion. Due to the osmotic effect of glucose this results in significantly more urine being 
produced over 24 hours, in some cases an increase of just under ½ a litre.  These agents also 
reduce plasma insulin concentrations and increase plasma glucagon levels, increasing the rate 
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of lipolysis [40]. During exercise, lipolysis is increased further, and fluid is lost which can lead 
to ketone body formation and the potential risk of ketoacidosis. To date only one human 
study has looked at the interaction of SGLT-2 and exercise. This study looked at the effect of 
12 weeks of exercise training with placebo or SGLT-2 in sedentary euglycaemic overweight 
obese men and women.  It found that lactate levels rose more during acute exercise in the 
SGLT2 group when compared to the control group. The SGLT-2 group saw less improvement 
in insulin sensitivity and a worsening of the glucose response to an oral glucose tolerance 
tests [41]. No studies to date have looked at the effect of exercise on ketone body formation 
or reduction in HbA1c in people with type 2 diabetes on SGLT-2 inhibitors. 
Physical activity and acarbose 
Acarbose inhibits alpha glucosidase, reducing the rate at which starch and sucrose are 
digested and absorbed. This produces a small but clinically significant reduction in blood 
glucose. In 105 elderly participants (90% men) with type 2 diabetes of <2 years duration 
reported that participants taking acarbose, with or without other medication, experienced 
less of a reduction in blood glucose immediately after walking [42]. However, in a 12-week 
study in 62 participants, the addition of acarbose to physical activity improved HbA1c in 
comparison with physical activity alone [43]. 
Overall, interactions between drug therapy and physical activity have been identified but are 
not well understood. It cannot be assumed that physical activity and drug therapy will be 
synergistic, and it is vital that these interactions are identified and are considered when new 
drugs are developed and tested. Interactions between dietary intake and drugs have not yet 
been investigated in any detail. It is unclear whether potential interactions between physical 
activity and drugs or diet and drugs is often considered when treatment decisions are made 
in practice. 
3) What can diet, and physical activity achieve in comparison to drugs? 
Despite the benefits of diet and physical activity for type 2 diabetes, there appear to be few 
studies that directly compare lifestyle interventions to drug therapy, particularly in the longer 
term. Lifestyle studies have been conducted that use changes in glucose lowering medication 
as a primary outcome or use a pre-determined prescribing protocol and report changes in 
medication as a secondary outcome. Studies of this type, and those that compared diet and 
physical activity directly with medication use, of 12 months or greater duration, are 
summarised below with more detail in a supplementary table (S1). 
Studies that have compared diet and physical activity to drugs at diagnosis 
Medication initiation was a primary outcome for two long-term (>5years) studies [7, 16, 44]. 
The UKPDS reported only 8% of participants met treatment targets on diet alone at 9 years 
[44]. A Mediterranean diet with moderately restricted carbohydrate, that all participants had 
initiated medication by 8.1 years [7]. In a shorter randomised controlled trial, Andrews et al 
[5] made changes to medication according to protocol and reported that the intervention 
groups achieved a greater reduction in HbA1c with fewer glucose lowering drugs. In addition, 
the Look Ahead study (which did not have a pre-determined protocol for prescribing glucose 
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lowering medication), found that the intervention group took fewer medications, with a 
reduction of 14% for glucose lowering medication at 10 years [8]. 
Studies that have compared diet and physical activity to drugs at later point  
Balducci et al [45] and Johansen et al [46] conducted physical activity interventions, in 
participants with type 2 diabetes of any duration or up to 10yrs respectively. Both studies 
adjusted medication to meet target levels and found that HbA1c was more likely to improve 
in the intervention group, whilst medication use decreased. A secondary analysis of the latter 
study found that participants in the intervention arm were more likely to experience 
remission[47]. Baptista et al [48] conducted a cohort study of older adults with type 2 diabetes 
of any duration, to investigate the effects of an exercise programme and found that only 
participants who were not on medication at all, in this case metformin, showed an 
improvement in glycaemia.  
Other lifestyle studies have observed a reduction in medication use for participants in diet 
and physical activity interventions compared with standard care or less intensive lifestyle 
intervention. Notably, a systematic review of moderate and low carbohydrate interventions 
found that carbohydrate restriction is likely to reduce the need for medication in both the 
short and longer term (>12 months) [49]. 
Studies that have looked at adding diet and physical activity onto drugs 
The Today study [50] is one of the few studies in young people with type 2 diabetes. 
Participants aged 10-17yrs were randomly assigned to continued treatment with metformin 
alone or to metformin combined with rosiglitazone (4 mg twice a day) or a lifestyle-
intervention program focusing on weight loss through eating and activity behaviours. The 
primary outcome was loss of glycaemic control, defined as an HbA1c of at least 64mmol/mol 
(8%) for 6 months, or starting on insulin. Although participants in the metformin and lifestyle 
arm had the least gain in weight, there was no difference in glycaemic control between the 
lifestyle and metformin arm and the metformin only arm. In contrast to this, the metformin 
and rosiglitazone arm, despite the biggest gain in weight, achieved the best glycaemic control. 
Coppell et al [6] described a diet intervention in with HbA1c>53mmol/mol (7.4%), and found 
HbA1c improved, whilst medication use also decreased. Wisse et al [51] conducted a two year 
study of physical activity in sedentary adults with type 2 diabetes on insulin, with mean 
HbA1c>60mmol/mol (7.6%). No difference between the control and intervention group was 
observed for HbA1c or insulin use at the end of the study, but self-reported increase in 
physical activity was the same for both groups and may not have been high enough to impact 
on HbA1c.  
There are other interventions in people with poor glycaemic control that do not report on 
medication use or changes in medication for all participants. Ligtenberg et al [52] recruited 
58 adults, aged >55yrs, poorly controlled, despite treatment with oral medication or insulin. 
The intervention consisted of a 12-week supervised exercise program, followed by 14-weeks 
unsupervised. There was no difference in HbA1c between groups after the intervention, 
which may be due to unsupervised physical activity lacking the necessary intensity. Ten 
 
9 
Lifestyle vs drugs 
participants in each group were using insulin and two additional participants from the control 
group started insulin during the study. Changes to oral medication were not reported. The 
Centro Universitario Ricerca Interdipartimentale Attività Motoria study [53] was an intensive 
3 month lifestyle intervention, involving 26 x 90min gym sessions and a nutritional 
intervention consisting of regular advice sessions with a dietitian. Secondary analysis at 2-
year follow up of the cohort of 222 participants with type 2 diabetes found that HbA1c 
improved the most for people with poor control at baseline (-17 ± 16mmol/mol (-1.6 ± 1.5%), 
p<0.001) with no change to defined daily doses for antidiabetic drugs (-0.1 ± 0.6, p=0.16). 
Overall, there appear to be few interventions that compare lifestyle interventions with drug 
therapy. In general, most lifestyle interventions do not control the prescription of medication, 
many do not report on medication use, and drug trials do not report lifestyle changes. 
Therefore, it is difficult to draw firm conclusions as to how many people, if any, may be able 
to substitute diet and physical activity for drug therapy in the long term. However, studies do 
indicate that adding diet or diet and physical activity can be beneficial at later stages of the 
disease, even when diabetes is poorly controlled on medication. 
4) Individualised approach, stage, age, gender and ethnicity 
Role of lifestyle at different stages of diabetes management  
The literature reviewed indicates that implementing good dietary habits and regular physical 
activity on diagnosis can delay or reduce the need for medication for a significant proportion 
of people with type 2 diabetes. Therefore, guidelines to start everyone on medication 
immediately on diagnosis may not be appropriate. People newly diagnosed with type 2 
diabetes should be offered high quality diet and physical activity programmes that have been 
demonstrated to work in the community as a first line treatment, using proven behavioural 
strategies. 
It is not yet clear if remission achieved through weight loss can be maintained for the rest of 
an individual’s life. Evidence to date from studies of 5 to 10 years duration indicates that most 
people do require glucose lowering medication eventually. However, reinforcing diet and 
physical activity advice can improve HbA1c after medication has started, especially in people 
who are not well controlled. Diet and physical activity should be reinforced at each stage that 
drugs are considered and should be intensified for those who are unable to reach target on 
maximum therapy. Adherence to existing medication should be emphasised and health 
professionals should take time to explore concerns about polypharmacy and the timing of 
medications around meals. 
Does age change how lifestyle should be used? 
Many lifestyle interventions are conducted with participants with mean ages of around 55-
60yrs, although some have been conducted specifically in older people [48, 53]. The Look 
Ahead trial found that intensive lifestyle was more effective in older people (>65yrs) and 
speculated that this may be due to better adherence with the diet and physical activity 
guidelines [8]. These studies indicate that a focus on lifestyle can help improve HbA1c in all 
adult age groups, whilst either reducing the need for medication or keeping it unchanged. 
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However, if people with type 2 diabetes, particularly older people, start exercising, 
sulfonylureas and glinides should be avoided due to risk of hypoglycaemia. 
It appears that adolescents with type 2 diabetes may not benefit from intensive lifestyle in 
the same manner. Results from the Today study [50] indicate that intensifying drug therapy 
was more effective than intensifying lifestyle. Furthermore, the failure rates for metformin 
alone were higher than similar studies in adults [44], which the study authors think is unlikely 
to be due to adherence but may indicate that there are biological differences in treatment 
responses. Despite the lack of observed benefit for additional lifestyle, all participants in all 
three arms received a minimum of 4 hours of diabetes education that included lifestyle advice 
and were tested to ensure they understood it and there is no evidence that standard diet and 
physical activity advice is unnecessary. 
Does gender or ethnicity change how lifestyle should be used 
There appear to be few studies that consider the effect of gender or ethnicity in lifestyle 
interventions. It is not known whether men and women, or people from different ethnic 
backgrounds, following the same advice will achieve the same outcomes. For example, 
menopause may affect the response to drugs or lifestyle in type 2 diabetes and is poorly 
understood. The Look Ahead study reported little difference amongst people from different 
ethnicities [8]. The Today study [50] undertook both gender and ethnicity subgroup analysis 
and found that there was an interaction with drug treatment and gender and ethnicity but 
not with the addition of lifestyle. At present individually tailored advice, that takes account of 
cultural and gendered differences is necessary. In future, lifestyle intervention should be 
powered to examine interactions between gender and ethnicity and physical activity or diet. 
Implementation 
Type 2 diabetes is a complex condition that requires a commitment to self-care and 
engagement with life-long treatment that affects personal and social life. Despite available 
drug therapies, a choice of dietary approaches and an understanding of the benefits of 
physical activity, only around 30% of people with type 2 diabetes meet treatment targets [13]. 
Retrospective evaluation of participants in real world, primary care settings, using routinely 
collected data, found that a diabetes management program tended to stabilise rather than 
improve weight (0.07 kg, p=0.832) and HbA1c (0.3mmol/mol (0.03%), p=0.657) over 2 ½ 
years, and that physical activity levels did not change for 70% of participants [54]. Adherence 
to drug therapy is reported to be poor and people particularly dislike taking multiple 
medications [4]. 
It appears that for many people with type 2 diabetes, successes achieved in research 
interventions are not translating to routine clinical practice. A systematic review of reviews 
of lifestyle interventions [55] in people at high risk of type 2 diabetes found good evidence 
that adding social support (eg from family members) to interventions increased effectiveness. 
In addition, dietary change was found to benefit from providing instruction, establishing self-
monitoring, having strategies to prevent relapse and encouraging self-talk. Physical activity 
benefited from prompting of activity, establishing self-monitoring, individual tailoring of 
physical activity or counselling, goal setting, time-management strategies and encouraging 
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self-talk. However, this kind of best practice from research interventions often does not 
appear to track through into standard care and health professionals may not always be 
trained in behaviour change techniques.  
Conclusions and future directions 
We have presented a broad overview of the literature on what diet and physical activity can 
achieve in the management of type 2 diabetes, how diet and physical activity may interact 
with drug therapy and what the evidence is for diet and physical activity in comparison with 
drug therapy. Table 2 provides recommendations for future research. 
The available evidence indicates that diet and physical activity are of key importance in type 
2 diabetes and attention to them can improve glycaemic control and cardiovascular disease 
risk at all stages of the disease but may not be an alternative to drug therapy. However, most 
people with type 2 diabetes do not receive intensive lifestyle support and there is more work 
needed on how to maintain diet and lifestyle changes and how to provide this support within 
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Figure legends 
Figure 1: Effect of weight loss and regular exercise in type 2 diabetes 
